<DOC>
	<DOCNO>NCT03047226</DOCNO>
	<brief_summary>The purpose study determine proportion patient diagnose Lynch syndrome colorectal cancer patient loss stain immunohistochemistry ( IHC ) mismatch repair ( MMR ) proteins . Besides , study aim test specificity sensitivity detect microsatellite instability ( MSI ) next-generation sequencing , find consistency IHC MSI colorectal cancer patient China . In addition , researcher want analyze clinical characteristic germline mutation Lynch syndrome Chinese population .</brief_summary>
	<brief_title>Diagnosis Lynch Syndrome Based Next-generation Sequencing Colorectal Cancer</brief_title>
	<detailed_description>1 . Detect microsatellite instability ( next-generation sequencing PCR capillary electrophoresis ) germline mutation ( next-generation sequencing ) probands . 2 . Analyze test outcome clinical family information evaluate germline mutation status preliminarily : likely pathogenic germline mutation , variant uncertain significance , non-pathogenic germline mutation . 3 . Verify germline mutation blood relative whose proband know likely pathogenic germline mutation variant uncertain significance . 4 . Diagnose pathogenic germline mutation non-pathogenic germline mutation base clinical characteristic , family information germline mutation test outcome ( include outcome probands blood relative ) . Diagnose Lynch syndrome pathogenic germline mutation carrier include population . 5 . Analyze specificity sensitivity detect microsatellite instability ( MSI ) next-generation sequencing ; analyze consistency IHC MSI . 6 . Analyze clinical characteristic germline mutation Lynch syndrome Chinese population .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms , Hereditary Nonpolyposis</mesh_term>
	<criteria>For probands , inclusion criterion : All follow four point satisfy : Histological diagnosis colorectal cancer ; With loss stain immunohistochemistry mismatch repair ( MMR ) proteins ( MLH1 , MSH2 , MSH6 , PMS2 ) ; With sufficient tumor tissue normal tissue test ; Agree provide basic information , clinical information family history cancer information . For probands , exclusion criterion : With least one blood relative know pathogenic germline mutation ( ) . For blood relative verify germline mutation , inclusion criterion : All follow three point satisfy : First seconddegree blood relative probands germline mutation ( ) . With Sufficient tumor tissue normal tissue test . Agree provide basic information , clinical information family history cancer information . For blood relative verify germline mutation , exclusion criterion : Blood relative refuse test .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lynch Syndrome</keyword>
	<keyword>mismatch repair</keyword>
	<keyword>microsatellite instability</keyword>
	<keyword>next-generation sequencing</keyword>
	<keyword>immunohistochemistry</keyword>
</DOC>